1. Introduction
The integration of traditional knowledge with modern scientific research continues to uncover valuable natural compounds with potential health benefits. The rising incidence of chronic diseases due to aging and lifestyle changes underscores the need for effective treatments [
1]. Fungi, with their rich nutritional profile and therapeutic properties, offer promising avenues for addressing global health concerns, particularly oxidative stress. Leveraging ancient folk remedies, many of which form the basis of modern medications, can enhance our approach to managing and preventing these prevalent health issues [
2]. For instance, recent research has focused on natural products for the prevention and treatment of metabolic syndrome, with particular attention to medicinal mushrooms [
3,
4]. Among these, the
Ganoderma species, known for their extensive use in traditional medicine, have shown promising potential [
5,
6].
Ganoderma species, such as
G. resinaceum, have been documented to possess various bioactive compounds, including nortriterpenoids (lucidone A–F, H, I–K, ganosineniol B–C, ganoderense F, and ganosineniol), which exhibit a wide range of beneficial biological activities [
7]. These activities include anti-inflammatory, antioxidant, and antidiabetic effects, which are particularly relevant to combating the multifaceted aspects of metabolic syndrome [
5,
7].
Species belonging to the genus
Ganoderma (P. Karst.) have been utilized as a natural resource in Traditional Chinese Medicine (TCM) for over two hundred years [
2,
8]. Its utilization has primarily relied on observations and accounts of its efficacy in cancer prevention and treatment, combating infections, modulating the immune system, and regulating blood pressure, among other medicinal benefits [
5,
6]. The medicinal properties of
Ganoderma spp. primarily stem from the abundance of various bioactive compounds they produce, notably triterpenoids like ganoderic acids, which have been reported to exhibit anti-hypercholesterolemic, anticancer, hepatoprotective, antioxidant, anti-inflammatory, antimicrobial, and hypoglycemic properties [
9,
10].
G. resinaceum extracts have shown inhibitory effects against enzymes such as acetylcholinesterase, tyrosinase, α-amylase, and α-glucosidase [
11,
12]. Also, nortriterpenoids extracted from
Ganoderma species display a diverse range of biological activities, such as antitumor, anti-inflammatory, neurotrophic, hepatoprotective, and anti-HIV-1 protease effects [
7]. These properties are noteworthy due to their structural diversity and potential as models in pharmaceutical research. Additionally, polysaccharides such as β-glucans and phenolic compounds play significant roles, exhibiting anti-inflammatory, antimicrobial, antioxidant and antiproliferative [
5,
6,
11,
12,
13,
14,
15,
16,
17], while ergosterol peroxide has been shown to induce tumor cell death [
18]. Wang et al. [
8] proposed that the bioactive compounds from
G. pfeifferi and other
Ganoderma species may exert a synergistic effect, indicating that their medicinal properties typically result from the combination of multiple ingredients.
Ganoderma species, renowned for their medicinal properties, have been extensively studied for their various health benefits [
5,
6,
12,
15,
16,
19,
20,
21]. In 1889, Patouillard expanded the genus to include 48 species, while data from 2022 indicate that the genus now comprises 181 species [
22]. Among them,
G. lucidum is globally recognized, owing to its use in TCM as the “Mushroom of Immortality” [
23]. The genus is widely distributed across the globe, particularly in tropical and subtropical areas spanning Africa, America, Asia, and Europe [
24]. In Europe, the genus consists of seven species [
20], with
G. pfeifferi and
G. resinaceum being among the less studied species compared to
G. lucidum,
G. applanatum, and
G. adspersum, among others.
Regarding taxonomy of these species, Rašeta et al. [
12] claimed that
G. pfeifferi and
G. resinaceum, along with
G. subamboinense and three
G. lucidum strains from the United States and Taiwan, form a single monophyletic cluster based on phylogenetic analysis. This group is distinguished by its ability to produce chlamydospores in culture. Two selected species,
G. pfeifferi and
G. resinaceum are from genus
Ganoderma, which is the major genus of the
Ganodermataceae family (Polyporales, Basidiomycota), known for producing bioactive compounds such as triterpenoids, polysaccharides, sterols and phenolics [
6,
20].
Studies have also highlighted the efficacy of
Ganoderma extracts in improving insulin sensitivity, regulating lipid metabolism, and reducing inflammation, as key factors in the management of metabolic syndrome [
25,
26,
27,
28]. The bioactive compounds in
Ganoderma species can modulate multiple metabolic pathways in the body [
29], making
Ganoderma a promising candidate for the prevention and treatment of various chronic diseases [
30].
As of today, the focus on antioxidant, antimicrobial, and enzyme inhibition including in vitro antidiabetic activity [
11,
12,
13,
14,
16,
17,
19,
31,
32] has focused on new medicinal species
G. pfeifferi, originated from Serbia but also presents an autochthonous European species, and
G. resinaceum, distributed in Asia, and North Africa as well.
In our previous study, we presented findings on the use of (EtOH) and hot-water (H
2O) extracts in suspension form derived from
G. pfeifferi and
G. resinaceum, which showed potential for application in diabetes [
16]. Hence, the objective of this study was to conduct a thorough comparative assessment of the in vitro antiproliferative and in vivo lipid-lowering, and hepato- and nephroprotective characteristics of
G. pfeifferi and
G. resinaceum, an area notably deficient in current literature.
Author Contributions
Conceptualization, M.R.; methodology, M.R., M.K. (Marko Kebert), S.K. (Sonja Kaišarević), N.S. and S.V.; validation, M.R., M.K. (Marko Kebert), S.K. (Sonja Kaišarević), N.S. and S.V.; formal analysis, M.R., M.K. (Marko Kebert), N.S. and S.V.; investigation, M.R., J.M. and M.K. (Marko Kebert); resources, M.R., M.K. (Marko Kebert), S.K. (Sonja Kaišarević), N.S. and S.V.; data curation, M.R., M.K. (Marko Kebert), S.K. (Saša Kostić), N.S. and S.V.; writing-original draft preparation, M.R. and J.M.; writing-review and editing, M.R., J.M., M.K. (Marko Kebert), S.K. (Saša Kostić), S.K. (Sonja Kaišarević), N.S., S.V. and M.K. (Maja Karaman); visualization, M.R. and S.K. (Saša Kostić); supervision, M.R. and M.K. (Maja Karaman); project administration, M.R., N.S., and S.V. All authors have read and agreed to the published version of the manuscript.